Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Primary Headache Clear all
Completed Not applicable Interventional

Heartmath Migraine Study

NCT04077658
View directory record Official record
Conditions
Migraine
Interventions
HeartMath, Waitlist Control
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines

NCT00122278
View directory record Official record
Conditions
Migraine
Interventions
Dexamethasone, Placebo
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Manhattan, New York • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2018 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Phase 2 Interventional

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

NCT06323928
View directory record Official record
Conditions
Migraine
Interventions
Lu AG09222, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
28
States / cities
Hoover, Alabama • Carlsbad, California • Fullerton, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Results available

Ticagrelor Therapy for RefrACTORy Migraine Study

NCT02518464
View directory record Official record
Conditions
Migraine, Headache, Migraine Headache
Interventions
Ticagrelor 90 mg twice per day
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Jul 22, 2026, 10:42 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Aspirin Resistance in Women With Migraine

NCT01257893
View directory record Official record
Conditions
Episodic Migraine, Chronic Migraine
Interventions
Aspirin (acetylsalicylic acid), Placebo
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine

NCT01662492
View directory record Official record
Conditions
Migraine Disorders
Interventions
Botulinum toxin type A Dose 1, Botulinum toxin type A Dose 2, Placebo (Normal Saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years to 17 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Phoenix, Arizona • Fullerton, California • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Results available

Valproate Versus Ketorolac Versus Metoclopramide

NCT01267864
View directory record Official record
Conditions
Acute Migraine
Interventions
Metoclopramide, Ketorolac, Valproate
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

NCT01952574
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo, Erenumab PFS, Erenumab AI/Pen
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
41
States / cities
Phoenix, Arizona • Long Beach, California • National City, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Maximizing Outcomes in Treating Acute Migraine

NCT03896009
View directory record Official record
Conditions
Migraine
Interventions
AXS-07 (MoSEIC meloxicam and rizatriptan), Meloxicam, Rizatriptan, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine

NCT03108469
View directory record Official record
Conditions
Chronic Migraine
Interventions
IONIS-PKKRx (ISIS 546254), Placebo
Drug · Other
Lead sponsor
Smith, Timothy R., M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
City of Saint Peters, Missouri • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Not applicable Interventional

Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines

NCT03716505
View directory record Official record
Conditions
Migraine Disorders
Interventions
gammaCore Sapphire active, gammaCore Sapphire Sham
Device
Lead sponsor
ElectroCore INC
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
30
States / cities
Scottsdale, Arizona • Carlsbad, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Results available

Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

NCT04252742
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
31
States / cities
Long Beach, California • Los Angeles, California • Basalt, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function

NCT03040479
View directory record Official record
Conditions
Migraine
Interventions
lasmiditan 200 mg
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Results available

A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

NCT05127486
View directory record Official record
Conditions
Migraine, Episodic Migraine
Interventions
Galcanezumab, Rimegepant, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
77
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tempe, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Jul 22, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional Results available

Melatonin for Adolescent Migraine Prevention Study

NCT03150797
View directory record Official record
Conditions
Migraine
Interventions
Melatonin, Placebo oral capsule
Drug
Lead sponsor
Amy Gelfand
Other
Eligibility
10 Years to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Results available

Imaging the Migraine Brain Pre- and Post-Erenumab

NCT03773562
View directory record Official record
Conditions
Migraine
Interventions
Erenumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Not applicable Interventional

Abortive Effect of an Ear Insufflator on Migraine

NCT02614378
View directory record Official record
Conditions
Migraine
Interventions
air insufflation, placebo
Procedure
Lead sponsor
Carrick Institute for Graduate Studies
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Phoenix, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Jul 22, 2026, 10:42 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department

NCT03576820
View directory record Official record
Conditions
Migraine
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
10 Years to 20 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine

NCT02057315
View directory record Official record
Conditions
Migraine Headaches
Interventions
ELS-M11, Placebo
Drug
Lead sponsor
Achelios Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Ann Arbor, Michigan • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jul 22, 2026, 10:42 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Objectively Diagnose and Monitor Treatment of Light Sensitivity

NCT03694626
View directory record Official record
Conditions
Photophobia, Traumatic Brain Injury, Migraine
Interventions
Pupillography, Ocular Coherence Tomography (OCT), Wrist-watch sensor device, Videography, Electrophysiology
Device
Lead sponsor
Randy Kardon
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Not applicable Interventional

One-Day Intervention for Depression and Impairment in Migraine Patients

NCT02108678
View directory record Official record
Conditions
Migraine, Depression
Interventions
ACT-ME, Migraine Education Only
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Jul 22, 2026, 10:42 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Osteopathic Manipulative Techniques for the Treatment of Chronic Migraine Headaches

NCT04520425
View directory record Official record
Conditions
Chronic Migraine, Headache
Interventions
Osteopathic manipulative therapy
Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine

NCT04152083
View directory record Official record
Conditions
Migraine
Interventions
Eptinezumab, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Jul 22, 2026, 10:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vagus Nerve Stimulation and Stress Reduction Training for Migraine

NCT03592329
View directory record Official record
Conditions
Migraine
Interventions
Stress Reduction Training A, active tVNS, Stress Reduction Training B, sham tVNS
Behavioral · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
193 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 22, 2026, 10:42 AM EDT